MSTN and sarcopenia: These findings support a pathway in which critical illness, immobilization, and catabolic inflammation during COVID-19 raise myostatin, promoting acute sarcopenia and prolonged functional impairment; accordingly, increased myostatin after COVID-19 is associated with longer rehabilitation, greater muscle wasting risk, and poorer functional recovery [102,103,104].